Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: radium-223 dichloride versus androgen receptor pathway inhibitor in bone-dominant metastatic castration-resistant prostate cancer
2023-505830-89-00Phase 4Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 21
01
Overview
Phase 4, randomised, open-label trial of radium-223 dichloride, enzalutamide and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bayer. Primary endpoint: Overall survival. Started Aug 2020; status: completed.
02
Drugs
radium-223 dichlorideenzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-505830-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505830-89-00.